{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:17:56Z","timestamp":1790363876489,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.seizure.2023.01.013","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T23:03:44Z","timestamp":1674169424000},"page":"22-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The safety of perampanel in different disorders and doses: A meta-analysis"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-0423","authenticated-orcid":false,"given":"Ping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongning","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5357-7343","authenticated-orcid":false,"given":"Huizhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.seizure.2023.01.013_bib0001","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/pr.120.019539","article-title":"Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options","volume":"72","author":"L\u00f6scher","year":"2020","journal-title":"Pharmacol Rev"},{"issue":"10172","key":"10.1016\/j.seizure.2023.01.013_bib0002","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.seizure.2023.01.013_bib0003","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WCO.0000000000000803","article-title":"What has been the impact of new drug treatments on epilepsy?","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2023.01.013_bib0004","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.8b00322","article-title":"Modulation of AMPA receptor gating by the anticonvulsant drug, perampanel","volume":"10","author":"Yuan","year":"2018","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"10.1016\/j.seizure.2023.01.013_bib0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/biom10030464","article-title":"Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors","volume":"10","author":"Hanada","year":"2020","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.seizure.2023.01.013_bib0006","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","article-title":"Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2023.01.013_bib0007","unstructured":"FDA. Fycompa\u00ae(perampanel): highlights of prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202834s016,208277s004lbl.pdf; 2019 [accessed 15 September 2022]."},{"key":"10.1016\/j.seizure.2023.01.013_bib0008","unstructured":"EMA. Fycompa\u00ae(perampanel): summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fycompa-epar-product-information_en.pdf; 2022 [accessed 15 September 2022]."},{"issue":"2","key":"10.1016\/j.seizure.2023.01.013_bib0009","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00415-021-10670-y","article-title":"Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis","volume":"269","author":"Aizawa","year":"2022","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.seizure.2023.01.013_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/mds.22974","article-title":"Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study","volume":"25","author":"Eggert","year":"2010","journal-title":"Movement Disord"},{"issue":"2","key":"10.1016\/j.seizure.2023.01.013_bib0011","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mds.23983","article-title":"Perampanel, an AMPA antagonist, found to have no benefit in reducing \u201coff\u201d time in Parkinson's disease","volume":"27","author":"Lees","year":"2012","journal-title":"Movement Disord"},{"issue":"1","key":"10.1016\/j.seizure.2023.01.013_bib0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/WNF.0b013e318241520b","article-title":"Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone","volume":"35","author":"Rascol","year":"2012","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.1016\/j.seizure.2023.01.013_bib0013","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00415-017-8681-y","article-title":"Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis","volume":"265","author":"Lattanzi","year":"2018","journal-title":"J Neurol"},{"issue":"8","key":"10.1016\/j.seizure.2023.01.013_bib0014","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/ene.12170","article-title":"The adverse event profile of perampanel: meta-analysis of randomized controlled trials","volume":"20","author":"Zaccara","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2023.01.013_bib0015","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2023.01.013_bib0016","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.seizure.2023.01.013_bib0017","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2023.01.013_bib0018","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.seizure.2023.01.013_bib0019","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2023.01.013_bib0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2011.01588.x","article-title":"Tolerability and safety of perampanel: two randomized dose-escalation studies","volume":"125","author":"Krauss","year":"2012","journal-title":"Acta Neurol Scand"},{"issue":"18","key":"10.1016\/j.seizure.2023.01.013_bib0021","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.seizure.2023.01.013_bib0022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/epi.13279","article-title":"Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial","volume":"57","author":"Meador","year":"2016","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2023.01.013_bib0023","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ane.12883","article-title":"Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study","volume":"137","author":"Nishida","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2023.01.013_bib0024","unstructured":"The National Institutes of Health Clinical trial registry. An evaluation of the efficacy and safety of E2007 in patients with painful diabetic neuropathy, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00505284; 2013 [accessed 15 September 2022]."},{"key":"10.1016\/j.seizure.2023.01.013_bib0025","unstructured":"The National Institutes of Health Clinical trial registry. Efficacy and safety of E2007 in migraine prophylaxis, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00154063; 2015 [accessed 15 September 2022]."},{"key":"10.1016\/j.seizure.2023.01.013_bib0026","unstructured":"The National Institutes of Health Clinical trial registry. A study to explore the safety and tolerability of dose of E2007 up to a maximum of 8mg in patients with Parkinson's disease who experience end-of-dose wearing off motor fluctuations, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00165789; 2015 [accessed 15 September 2022]."},{"key":"10.1016\/j.seizure.2023.01.013_bib0027","unstructured":"The National Institutes of Health Clinical trial registry. Study of perampanel as adjunctive treatment for inadequately controlled seizures associated with Lennox-Gastaut Syndrome, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02834793; 2022 [accessed 15 September 2022]."},{"issue":"7","key":"10.1016\/j.seizure.2023.01.013_bib0028","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/epi.13417","article-title":"Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: arandomized study evaluating behavior, efficacy, and safety","volume":"57","author":"Lagae","year":"2016","journal-title":"Epilepsia"},{"issue":"S1","key":"10.1016\/j.seizure.2023.01.013_bib0029","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/epi.14642","article-title":"Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy","volume":"60","author":"Tsai","year":"2019","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2023.01.013_bib0030","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2023.01.013_bib0031","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1528-1167.2012.03589.x","article-title":"The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Zaccara","year":"2013","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2023.01.013_bib0032","first-page":"297","article-title":"The adverse event profile of zonisamide: a meta-analysis","volume":"128","author":"Verrotti","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2023.01.013_bib0033","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2015.07.004","article-title":"The adverse event profile of levetiracetam: a meta-analysis on children and adults","volume":"31","author":"Verrotti","year":"2015","journal-title":"Seizure"},{"issue":"10","key":"10.1016\/j.seizure.2023.01.013_bib0034","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40263-013-0091-9","article-title":"Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy","volume":"27","author":"Hsu","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2023.01.013_bib0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yebeh.2016.08.004","article-title":"Sleep quality and daytime sleepiness in patients treated with adjunctive perampanel for focal seizures","volume":"63","author":"Toledo","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.01.013_bib0036","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ebcr.2016.10.002","article-title":"Effect of adjunctive perampanel on the quality of sleep and daytime somnolence in patients with epilepsy","volume":"7","author":"Gonz\u00e1lez-Cuevas","year":"2016","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.seizure.2023.01.013_bib0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.yebeh.2016.10.033","article-title":"Effects of adjunctive perampanel on sleep quality, daytime somnolence and cognition in refractory focal epilepsy: further data","volume":"67","author":"Romigi","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.01.013_bib0038","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.seizure.2020.01.021","article-title":"Perampanel effect on sleep architecture in patients with epilepsy","volume":"76","author":"Rocamora","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2023.01.013_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107384","article-title":"Insomnia is less prevalent and less severe, independent of depressive symptoms, in patients with epilepsy treated with perampanel as an adjuvant","volume":"112","author":"Lee","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.01.013_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108380","article-title":"Does a psychiatric history play a role in the development of psychiatric adverse events to perampanel\u2026 and to placebo?","volume":"125","author":"Kanner","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.seizure.2023.01.013_bib0041","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jpsychires.2013.05.001","article-title":"Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects","volume":"47","author":"Coccaro","year":"2013","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.seizure.2023.01.013_bib0042","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jpba.2017.11.008","article-title":"Pharmacokinetics and brain uptake study of novel AMPA receptor antagonist perampanel in SD rats using a validated UHPLC-QTOF-MS method","volume":"149","author":"Paul","year":"2018","journal-title":"J Pharmaceut Biomed"},{"issue":"1","key":"10.1016\/j.seizure.2023.01.013_bib0043","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/epi.13600","article-title":"Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies","volume":"58","author":"Leppik","year":"2017","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2023.01.013_bib0044","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40272-022-00505-2","article-title":"Impact of antiseizure medications on appetite and weight in children","volume":"24","author":"Buraniqi","year":"2022","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.seizure.2023.01.013_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2019.02.011","article-title":"Perampanel-induced weight gain depends on level of intellectual disability and its serum concentration","volume":"152","author":"Iwaki","year":"2019","journal-title":"Epilepsy Res"},{"issue":"20","key":"10.1016\/j.seizure.2023.01.013_bib0046","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1523\/JNEUROSCI.0115-14.2014","article-title":"Glucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA\/Kainate signaling","volume":"34","author":"Mietlicki-Baase","year":"2014","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.seizure.2023.01.013_bib0047","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2023.01.013_bib0048","article-title":"Lamotrigine add-on for drug-resistant partial epilepsy","volume":"2016","author":"Ramaratnam","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.seizure.2023.01.013_bib0049","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"issue":"19","key":"10.1016\/j.seizure.2023.01.013_bib0050","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","article-title":"Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2023.01.013_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108885","article-title":"Perampanel monotherapy for the treatment of epilepsy: clinical trial and real-world evidence","volume":"136","author":"Yamamoto","year":"2022","journal-title":"Epilepsy Behav"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123000201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123000201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:01:46Z","timestamp":1761012106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131123000201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":51,"alternative-id":["S1059131123000201"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2023.01.013","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety of perampanel in different disorders and doses: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2023.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}